ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Halberd Corp (PK)

Halberd Corp (PK) (HALB)

0.0055
0.0003
(5.77%)
Closed September 20 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.0055
Bid
0.0047
Ask
0.0055
Volume
445,261
0.0045 Day's Range 0.0055
0.003 52 Week Range 0.0121
Market Cap
Previous Close
0.0052
Open
0.00485
Last Trade
16363
@
0.0055
Last Trade Time
Financial Volume
$ 2,140
VWAP
0.004807
Average Volume (3m)
784,476
Shares Outstanding
635,880,000
Dividend Yield
-
PE Ratio
-14.29
Earnings Per Share (EPS)
-0
Revenue
3k
Net Profit
-454k

About Halberd Corp (PK)

Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurologic and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the speci... Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurologic and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid. Disease eradication via exposure to radio frequency, laser irradiation, or chemical bonding. The cleansed bodily fluids are then returned to the patient without deadly side effects found with injected or ingested medications. Halberds technology base is 4 issued patents and 22 pending patents: Current projects with planned submissions of abstracts to ARPA-H include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma * Extracorporeal eradication of antigens associated with cancer * Extracorporeal eradication of the 10 inflammatory cytokines & the excitatory neurotransmitter associated with Alzheimer's Disease, Parkinson's Disease & Epilepsy * Development of antibodies against Coronavirus & extracorporeal eradication of Covid antigens. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Huntington Woods, Michigan, USA
Founded
-
Halberd Corp (PK) is listed in the Medical Laboratories sector of the OTCMarkets with ticker HALB. The last closing price for Halberd (PK) was $0.01. Over the last year, Halberd (PK) shares have traded in a share price range of $ 0.003 to $ 0.0121.

Halberd (PK) currently has 635,880,000 shares outstanding. The market capitalization of Halberd (PK) is $3.31 million. Halberd (PK) has a price to earnings ratio (PE ratio) of -14.29.

HALB Latest News

WNRS - Winners Inc Maintains VERY BULLISH Posture - $0.05 Alternative To $50 Draft Kings (DKNG)

July 28, 2021 -- InvestorsHub NewsWire -- via pennymillions Winners, Inc. (WNRS) is growing. It’s signing one sports book after another as the legal online sports betting industry...

WSGF - With Vaycaychella's Q2 Launch Imminent, World Series of Golf Inc.'s Stock Is In Play

April 21, 2021 -- via MarketScreener.com   With World Series of Golf, Inc.'s (OTC Pink: WSGF) Vaycaychella nearing its planned Q2 launch, WSGF stock looks...

Immune Therapeutics, Inc.(Ticker: IMUN) Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs

October 21, 2020 -- InvestorsHub NewsWire -- via Stock Investor Wire -- Cytocom, Inc. , a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an...

Fintech SPAC Boom Could Ignite Existing Fintechs Like IQST

  October 19, 2020 -- InvestorsHub NewsWire -- via pennymillions/IQST -- This past summer saw multiple special purpose acquisition company (SPAC) IPOs targeting the...

PAOG CEO On MoneyTV This Friday Discussing Latest CBD Bio Pharma Developments

Sandusky, OH -- September 14, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon...

Halberd Corporation's Subsidiary Aspyre.com Enters Into Strategic Partnership With Positive Impact Magazine

Halberd Corporation's Subsidiary Aspyre.com Enters Into Strategic Partnership With Positive Impact Magazine PR Newswire SOUTHFIELD, Mich., July 29, 2014 SOUTHFIELD, Mich., July 29, 2014...

Halberd Corporation's New Subsidiary Aspyre.com Discusses Revenue Streams

Halberd Corporation's New Subsidiary Aspyre.com Discusses Revenue Streams PR Newswire SOUTHFIELD, Mich., July 22, 2014 SOUTHFIELD, Mich., July 22, 2014 /PRNewswire/ -- Halberd Corporation (OTC...

Halberd Corporation Acquires Crowd Connex Corporation And Its Subsidiary Aspyre.com

SOUTHFIELD, Mich., July 9, 2014 /PRNewswire/ - Halberd Corporation (OTC Market: HALB) acquires Tampa Bay based Crowd Connex Corporation. Crowd Connex Corporation owns Aspyre.com a secure online...

Halberd Corporation Responds To False Press Release Issued By SMSW Corporation

Halberd Corporation Responds To False Press Release Issued By SMSW Corporation PR Newswire SOUTHFIELD, Mich., July 8, 2014 SOUTHFIELD, Mich., July 8, 2014 /PRNewswire/ -- Halberd Corporation (OTC...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.00550.00630.004214114160.00557957CS
4-0.0005-8.333333333330.0060.00730.004210189310.00600764CS
12-0.0045-450.010.010.00427844760.00666592CS
26-0.0033-37.50.00880.01150.00429521360.00780029CS
52-0.004-42.10526315790.00950.01210.00311443350.00767636CS
156-0.027-83.07692307690.03250.03870.00314433910.01452223CS
2600.0047587.50.00080.1090.000446449590.02880311CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GENNGenesis Healthcare Inc (CE)
$ 0.0011
(109,900.00%)
2.64k
BYOCBeyond Commerce Inc (PK)
$ 0.0001
(9,900.00%)
32.65M
KLDOKaleido Biosciences Inc (CE)
$ 0.0001
(9,900.00%)
154
GWHPGlobal Wholehealth Partners Corporation (CE)
$ 0.0001
(9,900.00%)
19.55k
EGRNFChina Evergrande Group (CE)
$ 0.0001
(9,900.00%)
3.86k
THCBFTHC Biomed International Limited (CE)
$ 0.000001
(-100.00%)
100
ANTGFAdvantagewon Oil Corporation (CE)
$ 0.000001
(-99.99%)
2.46k
GKINGuskin Gold Corporation (CE)
$ 0.000001
(-99.97%)
1.5k
MOBOMobile Lads Corporation (CE)
$ 0.000001
(-99.97%)
40k
JUVAFJuva Life Inc (CE)
$ 0.000001
(-99.95%)
4.35k
IJJPIJJ Corporation (PK)
$ 0.0006
(100.00%)
305.25M
EPAZEpazz Inc (PK)
$ 0.0007
(40.00%)
257.54M
HCMCHealthier Choices Management Corporation (PK)
$ 0.0001
(0.00%)
219.94M
HMBLHUMBL Inc (PK)
$ 0.0002
(100.00%)
94.6M
RONNRonn Motor Group Inc (PK)
$ 0.0008
(-20.00%)
88.56M

HALB Discussion

View Posts
docsetc docsetc 3 hours ago
This one I bash since it's' been a scam since company inception, and that last PR reads like a bad deep fake. For no other reason. Proven scams I don't forget.
Losers hang on when others warn them. I don't bash any stock much at all, not even ones that are just performance dogs, but if they are proven scams like HALB (?) No problem and I don't do it often either.

Bug off kid. Adults here now to protect your $$$, if you have any left at this point.
👍️0
docsetc docsetc 3 hours ago
Sure. Have not owned a share of this for over 6 years now. After researching it closely, and discovering all of the scam operations, I go out at even money. The rest of you, I feel sorry for.

Your little blastoff rocket is grounded at this :"launch site".
👍️0
docsetc docsetc 3 hours ago
LMAO!
👍️0
work-n-hard work-n-hard 5 hours ago
You forgot bashing for cheap shares. (Just look at the volume. lol)
Who has to bash and then sit for who knows how long, on a bag of nothing? (Dead money is one of the dumbest things in Stinky Pinky Land.) SMH
Just wait for the PR and buy some. Hold for 5 mins. and release.
👍️0
squidster squidster 5 hours ago
Just waiting for news...
Gobble up those cheapies they won't be here long...
Just waiting on those government contracts...
HALB to the moon...
Did I miss any?
👍️ 1
Aero-man Aero-man 5 hours ago
That's right - when the PPS is manipulated down like this, load up. These game-playing schmendriks are doing longs a favor.
👍️0
work-n-hard work-n-hard 8 hours ago
Couldn't remember exactly when Hartless brought the show to this ticker, but approx. https://www.barchart.com/stocks/quotes/HALB/interactive-chart

Yep, we know what is about to happen. lol
Play the bounces.
👍️ 1
Jimmyarich Jimmyarich 9 hours ago
You are really tryin to get the share price down huh. Yeah if it drops I’m going to thank you for getting me more cheapies before it blows up. Keep talking bad about HALB. Everyone knows what’s about to happen 🚀
👍️ 2 🤑 1
docsetc docsetc 11 hours ago
Been the same central message here for 9 years now.
👍️0
docsetc docsetc 11 hours ago
A very poorly written PR. "Dr Vlad" (??) This sounds as bad as another couple of scams we've been monitoring. Anyone even attempt to get an email confirmation from 'Dr. Vlad" ??

Maybe with the bad grammar and misspellings, lack of corroboration, one may think this a scam PR?

Oh no, not here....
👍️0
retired early retired early 3 days ago
MM is shaking the tree. :) Lock those shares up boys.
👍️0
retired early retired early 4 days ago
I saw that. It's all coming together. :)
👍️0
pistol2 pistol2 5 days ago
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
8:00 AM ET 9/11/24 | GlobeNewswire
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI

JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd's LDX technology and Athena Corporation's WatchDawg(TM) monitoring technology.

Defense Atomics Corporation agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics' success using CRISPR methodology with overseas patients, this study is intended to substantiate the benefits of this technology in conjunction with Halberd/Athena's LDX PTSD and TBI/Brain Injury protocol.

"While we have observed statistically compelling results in PTSD/TBI management using CRISPR," says CEO Dr. Gabe Vlad of Defense Atomics Corp., "the ability to significantly integrate our treatment protocols with those of Halberd/Athena's medication and monitoring technologies is quite attractive. The WatchDawg monitoring allows us to acquire near real time (NRT) objective data with respect to the administration of CRISPR. From the preliminary data, there's no question that the LDX formulation adds clear adjunctive relief."

Dr. Mark Darrah, of Athena GTX added: "The early results of WatchDawg in LDX therapy are compelling and show that dovetailing therapies of many different forms with real data in brain health studies may hold the key to FDA clearance." He added, "It is much harder to argue against near real time data as opposed to mere recollections of subjective observations alone."

"We look forward to expanded use of LDX, and now that we can actually see the results documented by the WatchDawg technology in military veterans, the benefit in many modalities is limitless," says CEO of Halberd Corporation, William A. Hartman. Hartman continued, "Having commercial packaging of LDX and potentially CRISPR will allow us to market to physician groups even without formal FDA approval under current compounding laws, particularly with our access to, and relationships with, reputable and qualified compounding facilities. This product is useful for myriad disorders from PTSD, anxiety, depression, anger and addiction, to Chronic Covid, Alzheimer's, Chronic Kidney Disease (CKD), diabetes, and others. It has been shown to be remarkably without side-effects. These benefits are unique and extremely important to a successful endeavor. We now have a large quantity of commercially available product (LDX), enabling our team to aggressively market LDX to physician groups, hospitals, rehab centers...and something we haven't discussed and will expand on shortly, animal hospitals and clinics. This finally gives us great potential for real income and a go-to-market capability with actual product. This cannot at this point go directly to consumers, and must go through physicians, which is a potential market. Until then, the physician will be highly incentivized to utilize LDX, so that's a plus."

"While CRISPR is limited in FDA usage in the United States," ATP's Dr. Richard Goulding explains, "the FDA is looking for well-conceived studies to prove efficacy, particularly in areas where little to no other remedy is offered (Right to Try). LDX alone should be a go-to adjunct to all patients with anxiety and PTSD," says Dr. Goulding, adding, "we welcome the opportunity to clinically verify it."

Dr. Vlad added: "I have analyzed the preliminary data offered by the first tranche of patients from the WatchDawg pilot study, and realized that this is clearly the best fit for further research and justification for our CRISPR technology to be used in PTSD and those suffering brain injury. With WatchDawg, we can prove efficacy, or at least support it, all while demonstrating safety and efficacy from initial therapeutic intervention forward. What's exciting to me is the ability to see, thanks to the WatchDawg monitoring technology, real-time therapeutic effects on the individual. With WatchDawg, we would know immediately when something is working or not working, while quantitatively providing real-time data. That's a game changer. We have recently been awarded significant cash contracts and are thrilled to be able to have the funds to engage in this exciting trial with our new partners. Helping veterans suffering from suicidal ideation and PTSD has always been my fondest wish, especially since I am myself a veteran."

Dr. Vlad reports that "Defense Atomics Corp. successfully engineered specialty proprietary stem cells for this endeavor. Essentially what CRISPR does is to collect and utilize the patient's own blood and performs an extremely unique proprietary gene-editing process combined with stem cells to facilitate their goals. Historical results on patients have been quite compelling. I am committed to funding this study with Halberd/Athena. There are still significant regulatory hurdles to overcome, but we have the right personnel on board now to navigate these hurdles. Obviously, the key is to get the FDA the data and information they need to move this treatment forward. We also want veterans suffering from PTSD to have LDX available to them at low cost, so their medical teams can procure it from our existing charity, Stemofhope.com, since we have a commercial quantity of LDX available and all of the high-tech products utilized in the WatchDawg program monitoring platforms."

How large is the Market?

Databridgemarketresearch.com reports the global market for Post-Traumatic Stress Disorder (PTSD) treatments experienced steady growth. As of 2022
👍️0
mzasif mzasif 2 weeks ago
Keep loading these cheapies as they won't last long >> The 3rd PR will be out any day now, hopefully with much better news, that will drive the pps much higher into multiple pennies.

The last time it went down to .0032 it quickly bounced back and went to .0121 high.

DOD contracts will be announced soon and that will be the real game changer....ride to Silver ranges at the minimum.
👍️ 3 💯 1
pistol2 pistol2 2 weeks ago
there is 3 prs
👍️0
work-n-hard work-n-hard 2 weeks ago
It closed down on "good news" . Was busy, but guessing the translation is "here comes the next round of shares". SMH
We'll see, but expecting tomorrow we'll see OTCN on top of the Ask.

PS: The reasoning behind breaking into 2 PR's is, what ever doesn't sell with the 1st one, we expect to sell from the 2nd one.
👍️ 1
Aero-man Aero-man 2 weeks ago
More great news from Halberd Corp - this PPS is a great place to load more cheap shares.
Even our nay-saying board-shit-heads (you know who you are) can't refute the many positives happening with this innovative company!

https://halberdcorporation.com/halberd-letter-to-shareholders-patented-ldn-evolves-into-watchdawg-for-veteran-suicide-reduction/
👍️0
docsetc docsetc 4 weeks ago
And now Retired Early will cuss and swear a lot that his dung-heap isn't getting any more golden.
This is about to hit below .005 and get moldy there for another year.
👍️ 1 🤑 1
work-n-hard work-n-hard 4 weeks ago
Just when you think "you can't make this stuff up", someone does.
SMH
👍️0
squidster squidster 4 weeks ago
HALB was not awarded $700,000
"The DoD extended an invitation for us to submit a full application or proposal."
They were awarded the opportunity to submit an application for for research funding based on a white paper submitted...
👍️ 1
mzasif mzasif 4 weeks ago
Huge News Out!!! Dept. Of Defense (DOD) selected and awarded initial funding $700k to Halbert...much more to come.
https://finance.yahoo.com/news/halberd-corp-issues-letter-shareholders-120000153.html
👍️0
docsetc docsetc 1 month ago
Aero-man, broke on HALB, and destined to slide down the toilet with HALB. HALB's next mis-directed invention: A new Anal-Lube that serves as both a birth control for women, and an ED cure for Men. It's going to be called, "Aero-manless" and be sold in Walmart by X-mas!
👍️0
docsetc docsetc 1 month ago
Sure is, find any real proof of either!
👍️0
docsetc docsetc 1 month ago
Naaw, sorry you lost on that one.

It's been what (?) 16 years that HALB has been a major loser, liar and fraud, (proven). And now its concussion-aide nasal spray that's going to prove a profit.
Nope, never. Take that to the bank.

They can't even provide a shred of official evidence there's even trial testing happening.

I'm not a hater, I provide honest trips. When I saw what was really going on, and how bashers here had the facts in hand. I got out, barely breaking even.

I come back once in a while, noting who's advice on this board to never take.

GLTY
🤐 1
squidster squidster 1 month ago
Bit of a difference between Stage II clinical trail and phase II of a pre pilot study isn't there?😉
👍️0
docsetc docsetc 1 month ago
That's an internal release with no corroboration. Where are the published trials?
👍️0
retired early retired early 1 month ago
:) "Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results" :)
👍️ 1
docsetc docsetc 2 months ago
Bet no one here can even find a Stage II Trials award document anywhere for HALB.
👍️0
retired early retired early 2 months ago
All ultimate fighting guys and gals can give themselves a squirt just before they get an elbow or foot kick to the head. :)
👍️0
work-n-hard work-n-hard 2 months ago
lol Just hit late Jan. price level. Maybe we can load some 30's again?
👍️0
retired early retired early 2 months ago
Going to be HUGE. :)
👍️ 1
squidster squidster 2 months ago
"just waiting for news" 😆
👍️0
SLes1 SLes1 2 months ago
An item that all first responders should carry particularly paramedics and sports trainers however. All levels of sports all emergency crews everywhere!
👍️0
work-n-hard work-n-hard 2 months ago
" “We are optimistic that our successful Phase II testing will highlight the unique advantages of our patent-pending nasal spray...."
As far as encouragement goes, this part is all that matters at this time.
He did not say he was Confident and it is still Patent Pending. Should have just said, we need to sell some more shares, therefore, read this statement.
At like their previous endeavors, this will likely go nowhere IMO.
👍️0
Aero-man Aero-man 2 months ago
Let the Nay-Sayers chew on this for a while:

William A. Hartman, Halberd's Chairman, President, and CEO, added, “We are optimistic that our successful Phase II testing will highlight the unique advantages of our patent-pending nasal spray in preventing neurodegeneration following head trauma. Potential applications for Halberd’s nasal spray include military and civilian contact sports, law enforcement, hospitals, and emergency response units dealing with automobile accidents and falls. The market potential for this product is substantial if ongoing tests continue to support our initial optimism.”

These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
👍️ 2 🤑 1
retired early retired early 2 months ago
Set those shares with sell orders above a buck and keep the stocks from being played with by MM. :)
👍️ 1
AveragePenny AveragePenny 2 months ago
$HALB Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

https://www.globenewswire.com/en/news-release/2024/07/24/2917954/0/en/Halberd-Corp-s-OTC-HALB-Groundbreaking-Traumatic-Brain-Injury-TBI-Mitigation-Nasal-Spray-Shows-Promising-Phase-II-Initial-Test-Results.html

JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma.

Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-Ax™ nasal spray in producing positive outcomes when administered shortly after a TBI event. We included behavioral function as a key endpoint, which is significantly impacted by TBI.”

Dr. Carr elaborated, “Preliminary data reveal that higher impact forces lead to step-wise changes in motor activity levels. Notably, with one of the higher impact forces, TBI-induced motor activity changes were significantly improved when Tri-Ax™ was administered one hour post-impact. These findings suggest that the therapeutic benefits of Tri-Ax™ can be achieved when administered promptly after injury.”

William A. Hartman, Halberd's Chairman, President, and CEO, added, “We are optimistic that our successful Phase II testing will highlight the unique advantages of our patent-pending nasal spray in preventing neurodegeneration following head trauma. Potential applications for Halberd’s nasal spray include military and civilian contact sports, law enforcement, hospitals, and emergency response units dealing with automobile accidents and falls. The market potential for this product is substantial if ongoing tests continue to support our initial optimism.”

These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
👍️ 2 🤑 1
Jimmyarich Jimmyarich 2 months ago
That’s the registered agents address. That’s not their physical address
👍️0
retired early retired early 2 months ago
I would be expecting 100+ pennies when it's all ready for production. I can wait till then. :)
👍️0
Aero-man Aero-man 2 months ago
How about 100+ pennies.
👍️ 2 🤑 2
mzasif mzasif 2 months ago
Still waiting on the NEWS....DOD news will make this run into multiple pennies easily $$$
👍️ 1 🤑 1
Aero-man Aero-man 2 months ago
Just waiting for the news from the Halberd/AthenaGTX study. Athena is putting all the pieces of this puzzle together and looks to have their act together in dealing with the DOD.
👍️ 1
retired early retired early 2 months ago
I'm still locked and loaded. All of us need to set sell orders high and eliminate the MM from playing with our stocks. When we see acceptance we will be in buck land. :)
👍️ 1
AveragePenny AveragePenny 2 months ago
$HALB - "Halberd/AthenaGTX Data acquisition watches and sensors are up and running for the Watchdawg pilot study, ensuring comprehensive data collection. #HealthTech #Biotech"

$HALB Halberd/AthenaGTX Data acquisition watches and sensors are up and running for the Watchdawg pilot study, ensuring comprehensive data collection. #HealthTech #Biotech— Halberd Corporation (@HalberdC) July 9, 2024
👍️ 2 🤑 1
EHRjunkie EHRjunkie 2 months ago
In yesterdays' tweet: IRB established.

The Institutional Review Board reviews and monitors biomedical research involving human subjects (Halberd is conducting clinical trials on Veterans and active duty personel). In accordance with FDA regulations, an IRB has the authority to approve, require modifications (to secure approval), or disapprove research.
👍️ 3
AveragePenny AveragePenny 2 months ago
$HALB - "Halberd/AthenaGTX The cloud-based platform for the Watchdawg study is up and functional, with psychology therapy in place and IRB established. #DigitalHealth #Biotech"

$HALB Halberd/AthenaGTX The cloud-based platform for the Watchdawg study is up and functional, with psychology therapy in place and IRB established. #DigitalHealth #Biotech— Halberd Corporation (@HalberdC) July 8, 2024
👍️0
Aero-man Aero-man 3 months ago
"Halberd/AthenaGTX continue to recruit participants for the ongoing Watchdawg pilot study, now that compounded pharmaceuticals are manufactured and ready. #ClinicalTrials #Biotech #Watchdawg"

That's right - Halberd is moving the process forward.
👍️0
AveragePenny AveragePenny 3 months ago
$HALB - "Halberd/AthenaGTX continue to recruit participants for the ongoing Watchdawg pilot study, now that compounded pharmaceuticals are manufactured and ready. #ClinicalTrials #Biotech #Watchdawg"

$HALB Halberd/AthenaGTX continue to recruit participants for the ongoing Watchdawg pilot study, now that compounded pharmaceuticals are manufactured and ready. #ClinicalTrials #Biotech #Watchdawg— Halberd Corporation (@HalberdC) July 5, 2024
👍️ 2
Kool Aid Man Kool Aid Man 3 months ago
Apparently the Gouldings have slithered into another hole along with Tynan and Blum. Warning signs flashing IMO.

https://investorshub.advfn.com/boards/edit_msg.aspx?message_id=174702858
👍️0
mzasif mzasif 3 months ago
That means HALB will be getting something similar soon; either funding from Dept. of Defense, FDA approval, or even both.
👍️ 1

Your Recent History

Delayed Upgrade Clock